The present application generally relates to prosthetic valves for implantation in body channels. More particularly, the present application relates to a holder for a hybrid surgical prosthetic heart valve having a non-collapsible/non-expandable valve portion and a self-expanding anchoring stent.
In vertebrate animals, the heart is a hollow muscular organ having four pumping chambers—the left and right atria and the left and right ventricles—each provided with its own one-way valve to ensure that blood does not flow in the wrong direction. The mitral valve is between the left atrium and the left ventricle, the tricuspid valve between the right atrium and the right ventricle, the pulmonary valve is at the opening of the pulmonary artery, and the aortic valve is at the opening of the aorta above the left ventricle. The natural heart valves are each mounted in an annulus comprising dense fibrous rings attached either directly or indirectly to the atrial and ventricular muscle fibers. Each annulus defines a flow orifice.
Various surgical techniques may be used to repair or replace a diseased or damaged valve. Due to aortic stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve, either bioprosthetic or mechanical.
When the valve is replaced, surgical implantation of the prosthetic valve typically requires an open-chest surgery during which the heart is stopped and patient placed on cardiopulmonary bypass (a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. Due to these risks, a substantial number of patients with defective valves are deemed inoperable because their condition is too frail to withstand the procedure. By some estimates, about 30 to 50% of the subjects suffering from aortic stenosis who are older than 80 years cannot be operated on for aortic valve replacement.
Percutaneous and minimally-invasive surgical approaches, some of which avoid cardiopulmonary bypass altogether in “beating heart” procedures, are garnering intense attention. Although these remote implantation techniques have shown great promise for treating certain patients, replacing a valve via surgical intervention and bypass is still the preferred treatment procedure. One hurdle to the acceptance of remote implantation is resistance from doctors who are anxious about converting from an effective, if imperfect, regimen to a novel approach that promises great outcomes but is relatively foreign. In conjunction with the understandable caution exercised by surgeons in switching to new techniques of heart valve replacement, regulatory bodies around the world are moving slowly as well.
Accordingly, there is a need for a prosthetic valve that can be surgically implanted in a body channel in a more efficient procedure so as to reduce the time required on extracorporeal circulation. One solution especially for aortic valve replacement is provided by the Edwards Intuity valve system available from Edwards Lifesciences of Irvine, CA Aspects of the Edwards Intuity valve system are disclosed in U.S. Pat. No. 8,641,757 to Pintor, et al. The Edwards Intuity valve is a hybrid of a surgical valve and an expandable stent that helps secure the valve in place in a shorter amount of time. The implant process only requires three sutures which reduces the time-consuming process of tying knots. A delivery system advances the Edwards Intuity valve with the stent at the leading end until it is located within the left ventricle, at which point a balloon inflates to expand the stent against the ventricular wall. The long handle and delivery system design facilitate access through smaller incisions (mini-sternotomy or right anterior thoracotomy) than with conventional full sternotomies.
There remains a need for further innovative approaches like the Edwards Intuity valve system that combine the proven effectiveness of existing surgical valves and shorten the implant procedure time.
The present application discloses prosthetic valves and methods of use for replacing a defective native valve in a human heart. Certain embodiments are particularly well adapted for use in a surgical procedure for quickly and easily replacing a heart valve while minimizing time using extracorporeal circulation (e.g., bypass pump). In particular, the application discloses an advantageous system and method for holding and delivering a hybrid prosthetic heart in less time than previously was possible.
One aspect of the application is a combination of a prosthetic heart valve for implant at a heart valve annulus and a holder therefor. The combination includes a “hybrid” prosthetic heart valve having a valve member and a self-expandable anchoring stent. The valve member includes a non-expandable, non-collapsible annular support structure defining a flow orifice and an inflow end defining an inflow direction with an outflow direction opposite thereto. The valve member also has valve leaflets attached to the support structure and mounted to alternately open and close across the flow orifice. The self-expandable anchoring stent has a first or outflow end extending around the flow orifice and connected to the valve member at the inflow end of the support structure so that the first end maintains a fixed diameter. The anchoring stent also has a second or inflow end projecting in the inflow direction away from the support structure and having a relaxed, expanded shape defining a first peripheral size.
In a first embodiment, the valve holder connects by a first suture to the prosthetic heart valve, wherein the first suture extends around the second end of the anchoring stent and is placed under tension to constrict the second end to a second peripheral size smaller than the first peripheral size. The first suture desirably passes over a single cutting well on the valve holder such that severing the first suture at the single cutting well releases the tension therein and permits the second end of the anchoring stent to expand toward its first peripheral size.
In a second embodiment, the valve holder connects by a first suture to the prosthetic heart valve, wherein the first suture has a first free end attached to the valve holder, a middle portion that extends in a first length in the inflow direction, in a second length around the entire inflow end of the anchoring stent, and in a third length back to the valve holder alongside the first length, the first suture further having a fourth length that passes over a cutting well on the valve holder and ends in a second free end attached to the valve holder such that when the two free ends are attached to the valve holder the first suture is under tension and constricts the inflow end from a relaxed size to a smaller size.
In either valve-holder connection embodiment, the anchoring stent has a fabric covering, and wherein the first suture passes in a serpentine fashion through the fabric covering around the second or inflow end of the anchoring stent. The valve holders may be further connected by a second suture to the prosthetic heart valves, each valve holder including a plurality of legs (preferably three) that contact the valve member at the same number of locations having fabric incorporated into the valve member, and wherein the second suture passes circumferentially around the valve holder and threads through the fabric at the locations. Both the first and second sutures desirably pass over a single cutting well on the valve holder such that severing the first and second sutures at the single cutting well simultaneously releases the tension in the first suture, permitting the second end of the anchoring stent to expand toward its first peripheral size, and disconnects the valve holder from the prosthetic heart valve. The valve member support structure preferably has three commissure posts projecting in the outflow direction and three cusps therebetween that arc in the inflow direction, and the valve leaflets are flexible and partly supported by the commissure posts of the support structure. In this configuration, the valve holder includes a central hub and three legs that angle outward and in the inflow direction to contact the valve member at the three cusps, and wherein the first suture is tied at two free ends to a terminal foot of one of the holder legs. Also with this valve configuration, the valve holders further may be connected by a second suture to the prosthetic heart valve that passes circumferentially around the valve holder and threads through the fabric at the three cusps. The second suture may be tied at first and second free ends to the holder, and in between passes circumferentially around the hub of the holder and descends down each of the three legs to pass through two holes at a terminal foot thereof. The second suture is also preferably threaded through the fabric at each of the three cusps between the two holes, and circles completely around each leg between the hub and the respective foot.
A method of deploying a prosthetic heart valve for implant at a heart valve annulus disclosed herein comprises:
The method may also involve a second suture connecting the prosthetic heart valve to the holder, wherein both the first and second sutures pass over the cutting well on the valve holder such that severing the first and second sutures at the cutting well simultaneously releases the tension in the first suture, permitting the inflow end of the anchoring stent to expand toward its first peripheral size, and disconnects the valve holder from the prosthetic heart valve. The valve holder preferably includes a central hub and a plurality of legs that contact the valve member at the same number of locations having fabric incorporated into the valve member, wherein the second suture passes circumferentially around the valve holder and threads through the fabric at the locations. The second suture is desirably tied at first and second free ends to the holder, and in between passes circumferentially around the hub of the holder and descends down each of the legs to pass through two holes at a terminal foot thereof. The valve member support structure preferably has three commissure posts projecting in the outflow direction and three cusps therebetween that arc in the inflow direction, and the second suture is threaded through the fabric at each of the three cusps and between the two holes, and wherein the second suture circles completely around each leg between the hub and the respective foot.
A further understanding of the nature and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying drawings in which like parts bear like reference numerals.
The invention will now be explained and other advantages and features will appear with reference to the accompanying schematic drawings wherein:
The present disclosure provides a valve holder for hybrid prosthetic heart valves delivered by open-heart surgery, but which include features that decrease the duration of the treatment procedure. The prosthetic heart valves of the present invention are primarily intended to be delivered and implanted using surgical techniques, including the aforementioned open-heart surgery. There are a number of approaches in such surgeries, all of which result in the formation of a direct access pathway to the particular heart valve annulus. For clarification, a direct access pathway is one that permits direct (e.g., naked eye) visualization of the heart valve annulus.
The “hybrid” prosthetic heart valve has both non-expandable and expandable portions; specifically, an expandable anchoring stent or stent coupled to a non-expandable valve member. With this type of valve, the duration of the anchoring operation is greatly reduced as compared with a typical sewing procedure utilizing an array of sutures that must be knotted. The expandable anchoring stent may simply be radially expanded outward into contact with the implantation site, or may be provided with additional anchoring means, such as barbs. As stated, open-heart approach and cardiopulmonary bypass familiar to cardiac surgeons are used. However, due to the expandable anchoring stent, the time on bypass is greatly reduced by the relative speed of implant in contrast to the previous time-consuming knot-tying process. As mentioned above, an exemplary hybrid prosthetic heart valve is disclosed in U.S. Pat. No. 8,641,757 to Pintor, et al., filed Jun. 23, 2011, to which priority is claimed, and which is hereby expressly incorporated by reference herein.
For definitional purposes, the terms “stent” or “anchoring stent” refer to a structural component that is capable of anchoring to tissue of a heart valve annulus. The coupling stents described herein are most typically tubular stents, or stents having varying shapes or diameters. A stent is normally formed of a biocompatible metal frame, and may be formed of a plastically-expandable material such as stainless steel or cobalt-chromium, or a self-expandable material such as Nitinol. In the context of the present invention the stents are preferably made from laser-cut tubing of a self-expandable metal. It is conceivable, however, that the coupling stent could be separate self-expanding clamps or hooks that do not define a continuous periphery. Although such devices sacrifice some contact uniformity, and speed and ease of deployment, they could be configured to work in conjunction with a particular valve member.
The term “valve member” refers to that component of a heart valve that possesses the fluid occluding surfaces to prevent blood flow in one direction while permitting it in another. As mentioned above, various constructions of valve members are available, including those with flexible leaflets and those with rigid leaflets, or even a ball and cage arrangement. The leaflets may be bioprosthetic, synthetic, metallic, or other suitable expedients. In a preferred embodiment, the non-expandable valve member is an “off-the-shelf” standard surgical valve of the type that has been successfully implanted using sutures for many years, such as the Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences of Irvine, California, though the autonomous nature of the valve member is not absolutely required. In this sense, a “off-the-shelf” prosthetic heart valve is suitable for stand-alone sale and use, typically including a non-expandable, non-collapsible support structure having a sealing ring capable of being implanted using sutures through the sealing ring in an open-heart, surgical procedure.
As a point of further definition, the term “expandable” is used herein to refer to a component of the heart valve capable of expanding from a first, delivery diameter to a second, implantation diameter. An expandable structure, therefore, does not simply mean one that might undergo slight expansion from a rise in temperature, or other such incidental cause such as fluid dynamics acting on leaflets or commissures. Conversely, “non-expandable” should not be interpreted to mean completely rigid or dimensionally stable, as some slight expansion of conventional “non-expandable” heart valves, for example, may be observed.
An aortic valve replacement would be implanted in, or adjacent to, the aortic annulus, while a mitral valve replacement will be implanted at the mitral annulus. Certain features of the present invention are particularly advantageous for an aortic valve replacement. However, unless the combination is structurally impossible, or excluded by claim language, any of the heart valve embodiments described herein could be implanted in any body channel.
The exemplary hybrid prosthetic heart valve 20 of the present application desirably includes the valve member 22 with the anchoring stent 24 attached to and extending from an inflow end thereof. The valve member 22 is desirably non-collapsible and non-expandable, while the anchoring stent 24 may expand from a contracted state into the expanded state shown, as will be described. In the illustrated embodiment, the anchoring stent 24 features a series of axial struts with a chevron-shaped pattern of circumferential struts therebetween which expand when unrestrained to the shape shown in
The valve member 22 preferably includes a plurality of leaflets 30 supported by and extending inward from a cloth-covered inner support frame (not shown) that defines upstanding commissure posts 32 intermediate the same number of cusps 34. There are typically three commissure posts 32 alternating with three cusps 34 to support three leaflets 30 along each of the cusps, though only two or more than three are known. The leaflets 30 provide the occluding surfaces for the prosthetic heart valve 20 which ensure one-way blood flow through the valve. The illustrated valve member 22 includes a peripheral sealing ring 36 surrounding the inflow end thereof. The heart valve 20 is desirably for implantation at the aortic annulus and the sealing ring 36 therefore preferably has an undulating up and down shape around its periphery to match the native aortic annulus.
It should be noted that a sealing ring per se may not be necessary with the present heart valve as the primary function of such a component is normally to provide a platform through which to pass a number of anchoring sutures around the valve periphery. However, sutures are not used to implant the hybrid heart valve 20 except perhaps for a small number (e.g., 3) guide sutures. For instance, several tabs extending outward from the valve structure could be used for anchoring the guide sutures which take the place of the sealing ring for that purpose. To help prevent paravalvular leaking, a peripheral seal such as a fabric skirt as described below may be added in place of the sealing ring.
The leaflets 30 are desirably flexible, preferably bioprosthetic leaflets. For example, the valve leaflets 30 may be tissue from another human heart (cadaver), a cow (bovine), a pig (porcine valve) or a horse (equine). In some embodiments, the leaflets are pericardium or treated pericardium, for example, bovine, porcine, equine, or kangaroo. Alternatively, the valve member may comprise mechanical components rather than biological tissue. Although an autonomous (e.g., capable of stand-alone surgical implant) flexible leaflet valve member 22 is described and illustrated, alternative valve members that have rigid leaflets, or are not fully autonomous may be substituted.
In one embodiment, the valve member 22 comprises a Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences of Irvine, California. In another embodiment, the valve member 22 comprises a PERIMOUNT Magna® Aortic valve subjected to tissue treatment that permits dry packaging and sterilization, and that eliminates the need to rinse a preservative from the valves before implantation.
For bioprosthetic valves, an exemplary process includes storing the prosthetic heart valve 20 in a preservative solution after manufacture and prior to use. A preservative such as glutaraldehyde is provided within a storage jar. This “wet” storage arrangement applies to the illustrated heart valve 20 shown, which includes bioprosthetic leaflets. However, as mentioned above, the heart valve could also be used without a preservative solution for bioprosthetic leaflets that have been dried, for example, using suitable tissue treatments from Edwards Lifesciences, and also for mechanical valves.
The general function of the anchoring stent 24 is to provide the means to attach the prosthetic valve member 22 to the native aortic root. This attachment method is intended as an alternative to the present standard surgical method of suturing aortic valve bio-prostheses to the aortic valve annulus, and is accomplished in much less time. Further, this attachment method improves ease of use by eliminating most if not all suturing and knot tying. The anchoring stent 24 is formed of a self-expandable metallic member desirably covered by a polyester fabric to help seal against paravalvular leakage and promote tissue ingrowth once implanted within the annulus.
In a preferred embodiment, an inner fabric layer 26 immediately covering the anchoring stent 24 (inner fabric layer) comprises polytetrafluoroethylene (PTFE) cloth, such as TEFLON® PTFE (DuPont, Wilmington, Del.), although other biocompatible fabrics may be used. More particularly, the fabric 26 is a PTFE flat yarn. A sealing flange 28 comprises a much thicker material to provide prevention of paravalvular leakage. For instance, the sealing flange 28 is formed of a plush polymer, and made of polyethylene terephthalate (PET). More preferably, the material of the sealing flange 28 has a base yarn which is flat yarn 40/27, and a loop yarn extending therefrom made from PET 70/12 textured yarn both obtained from Atex Technologies Inc. of Pinebluff, NC The thickness of the sealing flange 28 material is desirably about 1.2 mm, uncompressed, while the thickness of the fabric 26 may be 50% or less of that. In alternative embodiments, different materials can be used from the covering layer 26 and the sealing flange 28, such as PTFE/cloth, cloth/cloth, or PTFE or cloth for the covering layer 26 and a swellable hydrophilic polymer such as an acrylic for the sealing flange 28. The sealing flange 28 is shown located around the upper or outflow end of the anchoring stent 24, although it may also cover the entire anchoring stent or be located around just the lower or inflow end.
As seen schematically in
Preferably, there is one upper connecting suture and one lower connecting suture, as shown, although only a single connecting suture or more than one of each are also possible. As will be explained, at least one suture functions to securely attach the holder to the heart valve, and one functions to maintain a self-expanding stent constricted. These functions may be accomplished with a single suture, though for the sake of stability and ease of assembly two are used, as is explained herein. Furthermore, although a particular path for both upper and lower connecting sutures are used for the particular holder shown, other suture paths can be used with other holders.
The three legs 56a, 56b, and 56c are identical and evenly spaced circumferentially around the central hub 52 (e.g., 120° spacing therebetween) in the illustrated example. With reference to
The upper connecting suture 60 has a first free end 86 that is tied to one of the outer walls 70 of the first holder leg 56a, as best seen in
As explained above, the suture 60 is first tied off at a left hand one of the vertical outer walls 70 on the first leg 56a. From there, as seen in
Now with reference to
In the next step, as seen in
Next, as seen in
Once the upper connecting suture 60 secures the holder 50 to the heart valve 20, the lower connecting suture 62 is attached and the anchoring stent 24 constricted, as will be explained with reference to
With reference to
Now with reference to
Finally, with reference to
As described above, an upper connecting suture 122 secures three legs 134 of the holder 50 to cusps of the valve 120. A lower connecting suture 124 attaches to the holder (not shown) passes downward to a lower end of the stent 132, and encircles and constricts the lower end when under tension. Both connecting sutures 122, 124 preferably pass over a single cutting well on the holder to enable simultaneous severing thereof and detachment of the holder and expansion of the stent 132, as seen in
While the certain embodiments are described and illustrated herein, it is to be understood that the words and drawings that have been used are words of description and not of limitation. Therefore, changes may be made within the appended claims without departing from the true scope of the disclosure.
This application is a continuation of U.S. patent application Ser. No. 16/429,651, filed Jun. 3, 2019, which is a continuation of U.S. patent application Ser. No. 15/451,203, filed Mar. 6, 2017, now U.S. Pat. No. 10,307,249, which is a continuation of U.S. patent application Ser. No. 14/700,007, filed Apr. 29, 2015, now U.S. Pat. No. 9,585,752, which claims the benefit of U.S. Patent Application No. 61/986,761, filed Apr. 30, 2014, the entire disclosures all of which are incorporated by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3143742 | Cromie | Aug 1964 | A |
3320972 | High et al. | May 1967 | A |
3371352 | Siposs et al. | Mar 1968 | A |
3409013 | Berry | Nov 1968 | A |
3546710 | Shumakov et al. | Dec 1970 | A |
3574865 | Hamaker | Apr 1971 | A |
3628535 | Ostrowsky et al. | Dec 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3686740 | Shiley | Aug 1972 | A |
3755823 | Hancock | Sep 1973 | A |
3839741 | Haller | Oct 1974 | A |
4035849 | Angell et al. | Jul 1977 | A |
4078468 | Civitello | Mar 1978 | A |
4079468 | Liotta et al. | Mar 1978 | A |
4084268 | Ionescu et al. | Apr 1978 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4172295 | Batten | Oct 1979 | A |
4217665 | Bex et al. | Aug 1980 | A |
4218782 | Rygg | Aug 1980 | A |
4259753 | Liotta et al. | Apr 1981 | A |
4340091 | Skelton et al. | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4364126 | Rosen et al. | Dec 1982 | A |
4388735 | Ionescu et al. | Jun 1983 | A |
4441216 | Ionescu et al. | Apr 1984 | A |
4451936 | Carpentier et al. | Jun 1984 | A |
4470157 | Love | Sep 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4501030 | Lane | Feb 1985 | A |
4506394 | Bedard | Mar 1985 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4605407 | Black et al. | Aug 1986 | A |
4626255 | Reichart et al. | Dec 1986 | A |
4629459 | Ionescu et al. | Dec 1986 | A |
4680031 | Alonso | Jul 1987 | A |
4687483 | Fisher et al. | Aug 1987 | A |
4702250 | Ovil et al. | Oct 1987 | A |
4705516 | Barone et al. | Nov 1987 | A |
4725274 | Lane et al. | Feb 1988 | A |
4731074 | Rousseau et al. | Mar 1988 | A |
4778461 | Pietsch et al. | Oct 1988 | A |
4790843 | Carpentier et al. | Dec 1988 | A |
4851000 | Gupta | Jul 1989 | A |
4865600 | Carpentier et al. | Sep 1989 | A |
4888009 | Lederman et al. | Dec 1989 | A |
4914097 | Oda et al. | Apr 1990 | A |
4960424 | Grooters | Oct 1990 | A |
4993428 | Arms | Feb 1991 | A |
5010892 | Colvin et al. | Apr 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5147391 | Lane | Sep 1992 | A |
5163955 | Love et al. | Nov 1992 | A |
5258023 | Reger | Nov 1993 | A |
5316016 | Adams et al. | May 1994 | A |
5326370 | Love et al. | Jul 1994 | A |
5326371 | Love et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5350420 | Cosgrove et al. | Sep 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5376112 | Duran | Dec 1994 | A |
5396887 | Imran | Mar 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411522 | Trott | May 1995 | A |
5423887 | Love et al. | Jun 1995 | A |
5425741 | Lemp et al. | Jun 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5443502 | Caudillo et al. | Aug 1995 | A |
5449384 | Johnson | Sep 1995 | A |
5449385 | Religa et al. | Sep 1995 | A |
5469868 | Reger | Nov 1995 | A |
5476510 | Eberhardt et al. | Dec 1995 | A |
5488789 | Religa et al. | Feb 1996 | A |
5489297 | Duran | Feb 1996 | A |
5489298 | Love et al. | Feb 1996 | A |
5500016 | Fisher | Mar 1996 | A |
5533515 | Coller et al. | Jul 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5562729 | Purdy et al. | Oct 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5573007 | Bobo, Sr. | Nov 1996 | A |
5578076 | Krueger et al. | Nov 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5618307 | Donlon et al. | Apr 1997 | A |
5626607 | Malecki et al. | May 1997 | A |
5628789 | Vanney et al. | May 1997 | A |
5693090 | Unsworth et al. | Dec 1997 | A |
5695503 | Krueger et al. | Dec 1997 | A |
5713952 | Vanney et al. | Feb 1998 | A |
5716370 | Williamson, IV et al. | Feb 1998 | A |
5728064 | Burns et al. | Mar 1998 | A |
5728151 | Garrison et al. | Mar 1998 | A |
5735894 | Krueger et al. | Apr 1998 | A |
5752522 | Murphy | May 1998 | A |
5755782 | Love et al. | May 1998 | A |
5766240 | Johnson | Jun 1998 | A |
5776187 | Krueger et al. | Jul 1998 | A |
5776188 | Shepherd et al. | Jul 1998 | A |
5800527 | Jansen et al. | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5814098 | Hinnenkamp et al. | Sep 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5824068 | Bugge | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5855563 | Kaplan et al. | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5865801 | Houser | Feb 1999 | A |
5891160 | Williamson, IV et al. | Apr 1999 | A |
5895420 | Mirsch, II et al. | Apr 1999 | A |
5902308 | Murphy | May 1999 | A |
5908450 | Gross et al. | Jun 1999 | A |
5919147 | Jain | Jul 1999 | A |
5921934 | Teo | Jul 1999 | A |
5921935 | Hickey | Jul 1999 | A |
5924984 | Rao | Jul 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5972004 | Williamson, IV et al. | Oct 1999 | A |
5984959 | Robertson et al. | Nov 1999 | A |
5984973 | Girard et al. | Nov 1999 | A |
6010531 | Donlon et al. | Jan 2000 | A |
6042607 | Williamson, IV et al. | Mar 2000 | A |
6059827 | Fenton, Jr. | May 2000 | A |
6066160 | Colvin et al. | May 2000 | A |
6074418 | Buchanan et al. | Jun 2000 | A |
6081737 | Shah | Jun 2000 | A |
6083179 | Oredsson | Jul 2000 | A |
6099475 | Seward et al. | Aug 2000 | A |
6106550 | Magovern et al. | Aug 2000 | A |
6110200 | Hinnenkamp | Aug 2000 | A |
6117091 | Young et al. | Sep 2000 | A |
6126007 | Kari et al. | Oct 2000 | A |
6264611 | Ishikawa et al. | Jul 2001 | B1 |
6319280 | Schoon | Nov 2001 | B1 |
6322526 | Rosenman et al. | Nov 2001 | B1 |
6350282 | Eberhardt | Feb 2002 | B1 |
6491624 | Lotfi | Dec 2002 | B1 |
6773457 | Ivancev et al. | Aug 2004 | B2 |
7018404 | Holmberg et al. | Mar 2006 | B2 |
7037333 | Myers et al. | May 2006 | B2 |
7189258 | Johnson et al. | Mar 2007 | B2 |
7998151 | St. Goar et al. | Aug 2011 | B2 |
8152844 | Rao et al. | Apr 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8323337 | Gurskis et al. | Dec 2012 | B2 |
8348998 | Pintor et al. | Jan 2013 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010039436 | Frazier et al. | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020026238 | Lane et al. | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020133226 | Marquez | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020188348 | DiMatteo et al. | Dec 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030036795 | Andersen et al. | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030149478 | Figulla et al. | Aug 2003 | A1 |
20030167089 | Lane | Sep 2003 | A1 |
20030236568 | Hojeibane et al. | Dec 2003 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040044406 | Woolfson et al. | Mar 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040122516 | Fogarty et al. | Jun 2004 | A1 |
20040167573 | Williamson et al. | Aug 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040206363 | McCarthy et al. | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210305 | Shu et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040225355 | Stevens | Nov 2004 | A1 |
20040236411 | Sarac et al. | Nov 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260390 | Sarac et al. | Dec 2004 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050043760 | Fogarty et al. | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050060029 | Le et al. | Mar 2005 | A1 |
20050065594 | DiMatteo et al. | Mar 2005 | A1 |
20050065614 | Stinson | Mar 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075713 | Biancucci et al. | Apr 2005 | A1 |
20050075717 | Nguyen et al. | Apr 2005 | A1 |
20050075718 | Nguyen et al. | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075720 | Nguyen et al. | Apr 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050080454 | Drews et al. | Apr 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137694 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050159811 | Lane | Jul 2005 | A1 |
20050165477 | Anduiza et al. | Jul 2005 | A1 |
20050165479 | Drews et al. | Jul 2005 | A1 |
20050182483 | Osborne et al. | Aug 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050192665 | Spenser et al. | Sep 2005 | A1 |
20050203616 | Cribier | Sep 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050203618 | Sharkawy et al. | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050222674 | Paine | Oct 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050240259 | Sisken et al. | Oct 2005 | A1 |
20050251252 | Stobie | Nov 2005 | A1 |
20050261765 | Liddicoat | Nov 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058871 | Zakay et al. | Mar 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060085060 | Campbell | Apr 2006 | A1 |
20060095125 | Chinn et al. | May 2006 | A1 |
20060122634 | Ino et al. | Jun 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060136054 | Berg et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060154230 | Cunanan et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060167543 | Bailey et al. | Jul 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060195185 | Lane et al. | Aug 2006 | A1 |
20060195186 | Drews et al. | Aug 2006 | A1 |
20060207031 | Cunanan et al. | Sep 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060235508 | Lane et al. | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060246888 | Bender et al. | Nov 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060271172 | Tehrani | Nov 2006 | A1 |
20060271175 | Woolfson et al. | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20060293745 | Carpentier et al. | Dec 2006 | A1 |
20070005129 | Damm et al. | Jan 2007 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070016285 | Lane et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070016288 | Gurskis et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070078509 | Lotfy | Apr 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070100440 | Figulla et al. | May 2007 | A1 |
20070129794 | Realyvasquez | Jun 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070150053 | Gurskis et al. | Jun 2007 | A1 |
20070156233 | Kapadia et al. | Jul 2007 | A1 |
20070162103 | Case et al. | Jul 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070179604 | Lane | Aug 2007 | A1 |
20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
20070198097 | Zegdi | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070203576 | Lee et al. | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070225801 | Drews et al. | Sep 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070239266 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20070244558 | Machiraju | Oct 2007 | A1 |
20070255398 | Yang et al. | Nov 2007 | A1 |
20070260305 | Drews et al. | Nov 2007 | A1 |
20070265701 | Gurskis et al. | Nov 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20070288089 | Gurskis et al. | Dec 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080033543 | Gurskis et al. | Feb 2008 | A1 |
20080065198 | Quintessenza | Mar 2008 | A1 |
20080119875 | Ino et al. | May 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080281411 | Berreklouw | Nov 2008 | A1 |
20080319543 | Lane | Dec 2008 | A1 |
20090036903 | Ino et al. | Feb 2009 | A1 |
20090192599 | Lane et al. | Jul 2009 | A1 |
20090192602 | Kuehn | Jul 2009 | A1 |
20090192603 | Kuehn | Jul 2009 | A1 |
20090192604 | Gloss | Jul 2009 | A1 |
20090192605 | Gloss et al. | Jul 2009 | A1 |
20090192606 | Gloss et al. | Jul 2009 | A1 |
20100161036 | Pintor et al. | Jun 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249908 | Chau et al. | Sep 2010 | A1 |
20100331972 | Pintor et al. | Dec 2010 | A1 |
20110022165 | Oba et al. | Jan 2011 | A1 |
20110147251 | Hodshon et al. | Jun 2011 | A1 |
20120065729 | Pintor et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120150288 | Hodshon et al. | Jun 2012 | A1 |
20120323317 | Karapetian et al. | Dec 2012 | A1 |
20130053949 | Pintor et al. | Feb 2013 | A1 |
20130116777 | Pintor et al. | May 2013 | A1 |
Number | Date | Country |
---|---|---|
0125393 | Nov 1984 | EP |
0143246 | Jun 1985 | EP |
1116573 | Jul 1985 | SU |
1697790 | Dec 1991 | SU |
9213502 | Aug 1992 | WO |
9742871 | Nov 1997 | WO |
Entry |
---|
International Search Report from corresponding PCT case No. PCT/US2015/028523 dated Aug. 3, 2015. |
Krakow, “3F Therapeutics, Inc. Announces the First Clinical Implantation of the 3F Enable Aortic Heart Valve.TM., a Patented, Sutureless Implantation, Replacement Heart Valve Intended to Save Valuable Surgery Time and Reduce Time RelatedComplications . . . ” Healthcare Sales & Marketing Network News Feed, Jan. 18, 2005, pp. 1-2. |
Sadowski, Jerzy; Kapelak, Boguslaw; Bartus, Krzysztof, “Sutureless Heart Valve Implantation—A Case Study,” Touch Briefings, 2005, pp. 48-50. |
Number | Date | Country | |
---|---|---|---|
20220362014 A1 | Nov 2022 | US |
Number | Date | Country | |
---|---|---|---|
61986761 | Apr 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16429651 | Jun 2019 | US |
Child | 17810182 | US | |
Parent | 15451203 | Mar 2017 | US |
Child | 16429651 | US | |
Parent | 14700007 | Apr 2015 | US |
Child | 15451203 | US |